These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 23458496)

  • 1. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II).
    Blumenfeld AM; Bloudek LM; Becker WJ; Buse DC; Varon SF; Maglinte GA; Wilcox TK; Kawata AK; Lipton RB
    Headache; 2013 Apr; 53(4):644-55. PubMed ID: 23458496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study.
    Buse D; Manack A; Serrano D; Reed M; Varon S; Turkel C; Lipton R
    Headache; 2012 Jan; 52(1):3-17. PubMed ID: 22106869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similarities and differences between chronic migraine and episodic migraine.
    Ferrari A; Leone S; Vergoni AV; Bertolini A; Sances G; Coccia CP; Ottani A; Pinetti D; Sternieri E
    Headache; 2007 Jan; 47(1):65-72. PubMed ID: 17355496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS).
    Stokes M; Becker WJ; Lipton RB; Sullivan SD; Wilcox TK; Wells L; Manack A; Proskorovsky I; Gladstone J; Buse DC; Varon SF; Goadsby PJ; Blumenfeld AM
    Headache; 2011; 51(7):1058-77. PubMed ID: 21762134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
    Kawata AK; Shah N; Poon JL; Shaffer S; Sapra S; Wilcox TK; Shah S; Tepper SJ; Dodick DW; Lipton RB
    Headache; 2021 Mar; 61(3):438-454. PubMed ID: 33594686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine.
    Bagley CL; Rendas-Baum R; Maglinte GA; Yang M; Varon SF; Lee J; Kosinski M
    Headache; 2012 Mar; 52(3):409-21. PubMed ID: 21929662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology of chronic migraine and mode of action of preventive medications.
    Mathew NT
    Headache; 2011; 51 Suppl 2():84-92. PubMed ID: 21770930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
    Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
    J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost and predictors of lost productive time in chronic migraine and episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.
    Serrano D; Manack AN; Reed ML; Buse DC; Varon SF; Lipton RB
    Value Health; 2013; 16(1):31-8. PubMed ID: 23337213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting.
    Yaldo AZ; Wertz DA; Rupnow MF; Quimbo RM
    Clin Ther; 2008 Dec; 30(12):2452-60. PubMed ID: 19167603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute treatment optimization in episodic and chronic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
    Serrano D; Buse DC; Manack Adams A; Reed ML; Lipton RB
    Headache; 2015 Apr; 55(4):502-18. PubMed ID: 25881676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent frequent nausea is associated with progression to chronic migraine: AMPP study results.
    Reed ML; Fanning KM; Serrano D; Buse DC; Lipton RB
    Headache; 2015 Jan; 55(1):76-87. PubMed ID: 25250833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
    Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
    Lipton RB; Buse DC; Serrano D; Holland S; Reed ML
    Headache; 2013 Sep; 53(8):1300-11. PubMed ID: 23879870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study.
    Buse DC; Manack AN; Fanning KM; Serrano D; Reed ML; Turkel CC; Lipton RB
    Headache; 2012; 52(10):1456-70. PubMed ID: 22830411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme.
    Ueda K; Ye W; Lombard L; Kuga A; Kim Y; Cotton S; Jackson J; Treuer T
    J Headache Pain; 2019 Jun; 20(1):68. PubMed ID: 31174464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment guidelines for preventive treatment of migraine].
    Treatment Guideline Subcommittee of the Taiwan Headache Society
    Acta Neurol Taiwan; 2008 Jun; 17(2):132-48. PubMed ID: 18686655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
    Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
    Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asthma is a risk factor for new onset chronic migraine: Results from the American migraine prevalence and prevention study.
    Martin VT; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
    Headache; 2016 Jan; 56(1):118-31. PubMed ID: 26581563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.